Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07492706 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

Study acronym: RSVVaccine
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age
Trial Details
NCT Number NCT07492706
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Conditions
(from sponsor)		 Respiratory Syncytial Virus (RSV)
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov